For individuals with symptomatic disease demanding therapy, ibrutinib is commonly suggested depending on four phase III randomized clinical trials comparing ibrutinib with chlorambucil monotherapy106 and also other typically applied CIT mixtures, particularly FCR, bendamustine additionally rituximab and chlorambucil furthermore obinutuzumab (ClbO).